ZGNX Share Price

Open 38.15 Change Price %
High 38.40 1 Day -0.60 -1.57
Low 37.20 1 Week 0.00 0.00
Close 37.50 1 Month -0.75 -1.96
Volume 746199 1 Year 26.10 228.95
52 Week High 41.80
52 Week Low 7.70
ZGNX Important Levels
Resistance 2 38.61
Resistance 1 38.15
Pivot 37.70
Support 1 36.85
Support 2 36.39
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Zogenix, Inc. (NASDAQ: ZGNX)

ZGNX Technical Analysis 5
As on 31st Oct 2017 ZGNX Share Price closed @ 37.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.66 & Strong Buy for SHORT-TERM with Stoploss of 23.93 we also expect STOCK to react on Following IMPORTANT LEVELS.
ZGNX Target for November
1st Target up-side 40.85
2nd Target up-side 43.2
3rd Target up-side 45.55
1st Target down-side 34.15
2nd Target down-side 31.8
3rd Target down-side 29.45
ZGNX Other Details
Segment EQ
Market Capital 232515696.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.zogenix.com
ZGNX Address
ZGNX
12400 High Bluff Drive
Suite 650
San Diego, CA 92130
United States
Phone: 858-259-1165
Fax: 858-259-1166
ZGNX Latest News
Interactive Technical Analysis Chart Zogenix, Inc. ( ZGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Zogenix, Inc.
ZGNX Business Profile
Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company�s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).